Physician profile
Michael Steenbergen
NPI 1013997337
$7,748.33
in general payments reported to CMS, 2019-2025
45 companies · $796 in 2025
The $796 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,437 · 2020: $985 · 2021: $1,449 · 2022: $1,100 · 2023: $845 · 2024: $1,136 · 2025: $796.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,737 · Education: $40.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,736.77 |
| Education | $40.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,130.84 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals Lp | $742.51 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $653.05 | 2019-2025 | |
| Amgen INC. | $498.26 | 2019-2025 | Repatha, Otezla, Otezla |
| Abbvie INC. | $494.15 | 2020-2025 | Vraylar, Linzess, Creon |
| Takeda Pharmaceuticals U.S.A., INC. | $375.53 | 2019-2025 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $345.88 | 2022-2025 | |
| Allergan, INC. | $345.53 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $294.04 | 2019-2021 | |
| Amarin Pharma, INC. | $251.38 | 2019-2022 | |
| Glaxosmithkline, LLC. | $229.18 | 2019-2024 | Shingrix, Arexvy, Bexsero |
| Astellas Pharma US INC | $205.18 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $190.18 | 2020-2023 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $186.79 | 2022-2025 | Rexulti, Abilify Maintena |
| Biohaven Pharmaceutical Holding Company Ltd. | $175.24 | 2022 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Steenbergen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.